There's an excellent opportunity for Canada to capitalize on its existing bone marrow transplantation centres. This is what we've done with the extension of our point-of-care manufacturing network, to roll out the manufacturing of expensive therapies, like CAR T cell, across the country. We're able to significantly lower the cost of this product, while at the same time capitalizing on existing infrastructure—
